Search

Displaying results 2761 - 2770 of 10000 in total
  1. Drug

    PR1 leukemia peptide vaccine

    go.drugbank.com/drugs/DB15276
    Investigational

    PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).

    Synonyms: L-VALINE, L-VALYL-L-LEUCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-ASPARAGINYL-L-VALYL-L-THREONYL-, PR-1
  2. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. … Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7.

    Synonyms: BCG65-E7, HPV 16 E7/HSP65 vaccine
  3. Drug

    Gancotamab

    go.drugbank.com/drugs/DB14784
    Investigational

    Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs.

  4. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

  5. Drug

    SMART101

    go.drugbank.com/drugs/DB18370
    Investigational

    SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.

  6. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. … It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.

    Categories: 4-Quinolones, Heterocyclic Compounds, 2-Ring
  7. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting the secondary solvent-front mutation _G2032R_ is 400

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  8. Target

    Bile acid-CoA:amino acid N-acyltransferase

    go.drugbank.com/bio_entities/BE0002303
    TargetEnzymeHumans

    Catalyzes the amidation of bile acids (BAs) with the amino acids taurine and glycine (PubMed:12239217, PubMed:12810727, PubMed:2037576, PubMed:8034703). More than 95% of the BAs are N-acyl amidates with glycine and taurine (PubMed:803470...

    Synonyms: BACAT
  9. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    ensuring high concentrations of 5-FU at a lower dose of tegafur [L933]. … Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by

    Synonyms: 1-(2-Tetrahydrofuryl)-5-fluorouracilInternational brands: Ai Yi, S-1
  10. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.